Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

UPDATE: Valeant Releases Details On Hospital Discount Plan For Heart Drugs

XTALKS VITALS NEWS

Hospital Pharmacy

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount.

Share this!

May 18, 2016 | by Sarah Massey, M.Sc.

Amid criticism over Valeant’s failure to deliver on promised hospital discounts for two of their heart drugs, the company has released the details of its rebate program for Isuprel and Nitropress. While these volume-based discounts were announced earlier this year, the company has faced considerable criticism from Congress over drug pricing and patient access.

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount. Valeant’s new Patient Access and Pricing committee has also vowed to neither increase the price of the drugs, nor decrease the discounts available.



While this is welcome news to hospital pharmacy administrators, Valeant has already raised the price of Isuprel and Nitropress by 720 percent and 310 percent, respectively, since acquiring the drugs in early 2015. Representatives from Valeant appeared in front of the Senate Aging Committee on April 27, where they were confronted by senators regarding the lack of hospitals that had received the discounts.

With the release of the statement earlier this week, it looks like Valeant is making strides to ensure hospitals get the drugs at reduced prices. According to the company, the discounts will likely be offered to group purchasing organizations as opposed to directly dealing with individual hospitals.

“Under this new program, the discounts we previously implemented for Nitropress and Isuprel will be simplified and more accessible,” said Joseph Papa, CEO of Valeant. “I understand the concerns our partners in the health care community have had about the pricing of these drugs, and we want to ensure hospitals and patients can get the drugs they need.

“I also want to thank the Senate Committee on Aging and the House Committee on Oversight and Government Reform for the attention they have brought to this issue, and specifically to gaps they identified in the previous program,” said Papa. “We are committed to getting this right.”


Keywords: Drug Pricing, Heart Drug, Hospital Pharmacy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.